Boxer Capital Management LLC purchased a new stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 671,358 shares of the company's stock, valued at approximately $15,106,000. Enliven Therapeutics accounts for 1.3% of Boxer Capital Management LLC's holdings, making the stock its 23rd biggest position. Boxer Capital Management LLC owned approximately 1.37% of Enliven Therapeutics as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its stake in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after purchasing an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Enliven Therapeutics in the fourth quarter valued at $97,000. ExodusPoint Capital Management LP purchased a new position in shares of Enliven Therapeutics during the 4th quarter valued at $200,000. China Universal Asset Management Co. Ltd. raised its stake in Enliven Therapeutics by 14.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock valued at $233,000 after acquiring an additional 1,275 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in Enliven Therapeutics by 17.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock valued at $307,000 after buying an additional 1,980 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.
Enliven Therapeutics Stock Performance
ELVN traded down $1.15 during trading on Wednesday, reaching $18.55. The stock had a trading volume of 20,208 shares, compared to its average volume of 260,109. The business has a 50-day moving average of $19.16 and a 200-day moving average of $22.26. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03. The stock has a market cap of $909.93 million, a PE ratio of -9.77 and a beta of 1.07.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million during the quarter. Equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.
Insider Buying and Selling
In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $16.07, for a total value of $80,350.00. Following the completion of the transaction, the insider now directly owns 997,688 shares in the company, valued at approximately $16,032,846.16. This represents a 0.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $21.93, for a total transaction of $146,207.31. Following the sale, the chief operating officer now directly owns 329,977 shares in the company, valued at $7,236,395.61. The trade was a 1.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 76,111 shares of company stock valued at $1,516,746 over the last three months. 29.20% of the stock is owned by company insiders.
Analysts Set New Price Targets
Separately, HC Wainwright upped their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a report on Friday, March 21st.
Get Our Latest Stock Report on Enliven Therapeutics
Enliven Therapeutics Profile
(
Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
